These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7933234)

  • 1. Expectant management of clinically localized prostatic cancer.
    Warner J; Whitmore WF
    J Urol; 1994 Nov; 152(5 Pt 2):1761-5. PubMed ID: 7933234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expectant management of localized prostatic cancer.
    Whitmore WF; Warner JA; Thompson IM
    Cancer; 1991 Feb; 67(4):1091-6. PubMed ID: 1991257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of early stage prostate cancer: conservative management--delayed therapy.
    Chodak GW
    Important Adv Oncol; 1994; ():241-4. PubMed ID: 8206492
    [No Abstract]   [Full Text] [Related]  

  • 5. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
    Zincke H; Oesterling JE; Blute ML; Bergstralh EJ; Myers RP; Barrett DM
    J Urol; 1994 Nov; 152(5 Pt 2):1850-7. PubMed ID: 7523733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors.
    Zincke H; Bergstralh EJ; Larson-Keller JJ; Farrow GM; Myers RP; Lieber MM; Barrett DM; Rife CC; Gonchoroff NJ
    Cancer; 1992 Jul; 70(1 Suppl):311-23. PubMed ID: 1600493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment: expected duration stage by stage.
    Schröder FH
    Prostate Suppl; 2000; 10():26-31. PubMed ID: 11056490
    [No Abstract]   [Full Text] [Related]  

  • 17. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
    Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
    Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
    Yossepowitch O
    Eur Urol; 2007 Aug; 52(2):453. PubMed ID: 17674435
    [No Abstract]   [Full Text] [Related]  

  • 19. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of randomized trials in localized prostate cancer.
    Alibhai SM; Klotz LH
    Can J Urol; 2004 Feb; 11(1):2110-7. PubMed ID: 15003149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.